Denali Advisors LLC Has $5.17 Million Stock Position in Eli Lilly and Company $LLY

Denali Advisors LLC lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 47.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,772 shares of the company’s stock after selling 6,004 shares during the period. Denali Advisors LLC’s holdings in Eli Lilly and Company were worth $5,167,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Capital Planning Advisors LLC increased its holdings in Eli Lilly and Company by 25.4% during the third quarter. Capital Planning Advisors LLC now owns 3,744 shares of the company’s stock worth $2,857,000 after buying an additional 759 shares during the last quarter. Northwestern Mutual Investment Management Company LLC lifted its stake in Eli Lilly and Company by 1.0% in the third quarter. Northwestern Mutual Investment Management Company LLC now owns 25,338 shares of the company’s stock valued at $19,333,000 after acquiring an additional 244 shares during the last quarter. Amica Retiree Medical Trust grew its position in shares of Eli Lilly and Company by 12.6% in the 3rd quarter. Amica Retiree Medical Trust now owns 1,440 shares of the company’s stock valued at $1,099,000 after acquiring an additional 161 shares during the period. Phillips Wealth Planners LLC increased its stake in shares of Eli Lilly and Company by 22.7% during the 3rd quarter. Phillips Wealth Planners LLC now owns 324 shares of the company’s stock worth $274,000 after purchasing an additional 60 shares during the last quarter. Finally, Amica Mutual Insurance Co. raised its holdings in shares of Eli Lilly and Company by 14.3% in the 3rd quarter. Amica Mutual Insurance Co. now owns 16,185 shares of the company’s stock valued at $12,349,000 after purchasing an additional 2,031 shares during the period. 82.53% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently commented on LLY. Truist Financial set a $1,281.00 price target on Eli Lilly and Company in a report on Thursday, February 5th. Wall Street Zen downgraded Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 31st. TD Cowen boosted their target price on Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a “buy” rating in a report on Thursday, January 29th. Morgan Stanley raised their price target on Eli Lilly and Company from $1,290.00 to $1,313.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Finally, Zacks Research cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,218.88.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,040.12 on Monday. The stock has a 50 day simple moving average of $1,052.39 and a 200 day simple moving average of $908.35. The stock has a market cap of $981.21 billion, a P/E ratio of 45.32, a PEG ratio of 1.21 and a beta of 0.39. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The firm had revenue of $19.29 billion for the quarter, compared to analysts’ expectations of $17.85 billion. During the same quarter last year, the business earned $5.32 EPS. The company’s quarterly revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be paid a $1.73 dividend. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. This represents a $6.92 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is presently 30.15%.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly retains a buy rating on a strong 2026 outlook after robust results and guidance, reinforcing investor confidence in revenue growth from GLP-1s and other pipeline drivers. Eli Lilly (LLY) Retains Buy Rating on Strong 2026 Outlook
• Positive Sentiment: Analyst upgrades — including Freedom Capital moving LLY from hold to buy — add near-term demand/support for the stock and reflect bullish sentiment after the company’s recent results. Eli Lilly and Company (LLY) Gets Upgraded to Buy From Hold by Freedom Capital
• Positive Sentiment: Lilly announced a transformational acquisition (Orna Therapeutics) to expand its RNA platform — diversifies the pipeline and signals management is investing to extend long-term growth beyond GLP‑1s. Eli Lilly and Company (LLY) to Acquire Orna Therapeutics in $2.4B Deal to Expand RNA Pipeline
• Positive Sentiment: Local approval for a major manufacturing investment (Huntsville council sign-off) supports capacity expansion for anticipated product demand and signals commitment to scale production. Huntsville City Council approves Eli Lilly agreement to build $6 billion manufacturing plant
• Neutral Sentiment: Lilly has built roughly $1.5B of inventory of its experimental oral weight‑loss pill (orforglipron) ahead of an FDA decision expected in April — signals confidence but raises execution/FDA risk until approval. Eli Lilly builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision
• Neutral Sentiment: Separate reports note Lilly prepared $1B+ in orforglipron stock and larger pre-launch inventories — operationally positive if approved, but costly if rollout is delayed or restricted. Lilly Prepares $1B+ Orforglipron Stock Ahead of Approval as Novo Brings Wegovy Pill Overseas
• Neutral Sentiment: Early-stage clinical readouts (e.g., Brenipatide in schizophrenia) add optional upside to valuation if positive, but remain speculative until later‑stage data. Eli Lilly’s Brenipatide Trial Adds Quiet Optionality in Schizophrenia
• Negative Sentiment: Competitive pressure: reports that Novo Nordisk is moving its Wegovy pill/shot strategies (selling overseas and in vials) highlight intensified competition in the obesity market, which could pressure pricing and share. Novo to follow Lilly and sell obesity shot Wegovy in vials

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.